118 related articles for article (PubMed ID: 38319051)
1. The potential of some functional group compounds substituted 8-Manzamine A as RSK1 inhibitors: molecular docking and molecular dynamics simulations.
Zayed AOH; Altarabeen M; AlShamaileh E; Zain SM
J Biomol Struct Dyn; 2024 Feb; ():1-10. PubMed ID: 38319051
[TBL] [Abstract][Full Text] [Related]
2. Discovery of potential RSK1 inhibitors for cancer therapy using virtual screening, molecular docking, molecular dynamics simulation, and MM/GBSA calculations.
Kalin S; Comert Onder F
J Biomol Struct Dyn; 2023 Dec; ():1-21. PubMed ID: 38084766
[TBL] [Abstract][Full Text] [Related]
3. Identification of some novel oxazine substituted 9-anilinoacridines as SARS-CoV-2 inhibitors for COVID-19 by molecular docking, free energy calculation and molecular dynamics studies.
Rajagopal K; Varakumar P; Aparna B; Byran G; Jupudi S
J Biomol Struct Dyn; 2021 Sep; 39(15):5551-5562. PubMed ID: 32720578
[TBL] [Abstract][Full Text] [Related]
4. RSK1 vs. RSK2 Inhibitory Activity of the Marine β-Carboline Alkaloid Manzamine A: A Biochemical, Cervical Cancer Protein Expression, and Computational Study.
Mayer AMS; Hall ML; Lach J; Clifford J; Chandrasena K; Canton C; Kontoyianni M; Choo YM; Karan D; Hamann MT
Mar Drugs; 2021 Sep; 19(9):. PubMed ID: 34564169
[TBL] [Abstract][Full Text] [Related]
5. In-silico Design, ADMET Screening, Prime MM-GBSA Binding Free Energy Calculation and MD Simulation of Some Novel Phenothiazines as 5HT6R Antagonists Targeting Alzheimer's Disease.
V P; A M; N R
Curr Comput Aided Drug Des; 2024 Jan; ():. PubMed ID: 38204222
[TBL] [Abstract][Full Text] [Related]
6. Marine-Based Candidates as Potential RSK1 Inhibitors: A Computational Study.
AlTarabeen M; Al-Balas Q; Albohy A; Müller WEG; Proksch P
Molecules; 2022 Dec; 28(1):. PubMed ID: 36615396
[TBL] [Abstract][Full Text] [Related]
7. In-silico screening and molecular dynamics simulation of quinazolinone derivatives as PARP1 and STAT3 dual inhibitors: a novel DML approaches.
Dilipkumar S; Karthik V; Dk S; Gowramma B; Lakshmanan K
J Biomol Struct Dyn; 2023 Sep; ():1-11. PubMed ID: 37735921
[TBL] [Abstract][Full Text] [Related]
8. An
Malkaje S; Srinivasa MG; Deshpande N S; Navada S; Revanasiddappa Bc
Curr Drug Res Rev; 2023; 15(1):88-100. PubMed ID: 36017854
[TBL] [Abstract][Full Text] [Related]
9. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.
Chaudhari HK; Pahelkar A
Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898
[TBL] [Abstract][Full Text] [Related]
10. Lead optimization of
Ojo OA; Adegboyega AE; Taiwo OA; Olowosoke CB; Johnson GI; Umedum NL; Onuh K; Adeduro MN; Nwobodo VO; Elekan AO; Alemika TE; Johnson TO
J Biomol Struct Dyn; 2023 Dec; ():1-15. PubMed ID: 38109128
[TBL] [Abstract][Full Text] [Related]
11. Pyrazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer - An in-silico approach.
Rajagopal K; Sri VB; Byran G; Gomathi S
Curr Drug Res Rev; 2022; 14(1):61-72. PubMed ID: 34139975
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, extra-precision docking, and molecular dynamics simulation studies of pyrrolidin-2-one derivatives as potential acetylcholinesterase inhibitors.
Gupta M; Kumar A; Prasun C; Nair MS; Kini SG; Yadav D; Nain S
J Biomol Struct Dyn; 2023; 41(13):6282-6294. PubMed ID: 35921217
[TBL] [Abstract][Full Text] [Related]
13. Targeting EGFR, RSK1, RAF1, PARP2 and LIN28B for several cancer type therapies with newly synthesized pyrazole derivatives via a computational study.
Bennani FE; Doudach L; Karrouchi K; Tarib A; Rudd CE; Ansar M; Faouzi MEA
J Biomol Struct Dyn; 2023 Jun; 41(9):4194-4218. PubMed ID: 35442150
[TBL] [Abstract][Full Text] [Related]
14.
Maurya AK; Mishra N
J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
[TBL] [Abstract][Full Text] [Related]
15. Identification of tyrosine kinase inhibitors from Panax bipinnatifidus and Panax pseudoginseng for RTK-HER2 and VEGFR2 receptors, by in silico approach.
Paul D; Mahanta S; Tag H; Das SK; Das Gupta D; Tanti B; Ananthan R; Das R; Jambhulkar S; Hui PK
Mol Divers; 2022 Aug; 26(4):1933-1955. PubMed ID: 34554395
[TBL] [Abstract][Full Text] [Related]
16. Virtual Screening of Novel Glucosamine-6-Phosphate Synthase Inhibitors.
Lather A; Sharma S; Khatkar A
Comb Chem High Throughput Screen; 2018; 21(3):182-193. PubMed ID: 29600755
[TBL] [Abstract][Full Text] [Related]
17. In-silico Design, ADMET Screening, MM-GBSA Binding Free Energy of Some Novel Isoxazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer.
Kalirajan R; Pandiselvi A; Gowramma B; Balachandran P
Curr Drug Res Rev; 2019; 11(2):118-128. PubMed ID: 31513003
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and molecular dynamics simulation studies of quinoline derivatives as protease inhibitors against SARS-CoV-2.
Singh VK; Chaurasia H; Kumari P; Som A; Mishra R; Srivastava R; Naaz F; Singh A; Singh RK
J Biomol Struct Dyn; 2022; 40(21):10519-10542. PubMed ID: 34253149
[TBL] [Abstract][Full Text] [Related]
19. Identification of potential inhibitors against
Gaur V; Kumar N; Vyas A; Chowdhury D; Singh J; Bera S
J Biomol Struct Dyn; 2023 Dec; ():1-11. PubMed ID: 38149858
[TBL] [Abstract][Full Text] [Related]
20. Benzothiazole derivatives as p53-MDM2 inhibitors:
N SD; Shivakumar ; Kumar D U; Ghate SD; Dixit SR; Awasthi A; Revanasiddappa BC
J Biomol Struct Dyn; 2023 Dec; ():1-12. PubMed ID: 38111168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
